In the present study we used comparative immuno-blotting of the ATM protein to investigate a cohort of cancer patients selected on the basis of their severe adverse reactions to adjuvant radiotherapy and compared these with control patients with no adverse reactions. The gene discussed is ATM; the disease is cancer.